Long-term survival in a patient with Li-Fraumeni syndrome–associated giant cell glioblastoma treated with nivolumab: illustrative case
Despite advances in treatment, the median survival of patients with GBM is only 15 months. This case highlights the potential of immunotherapy with PD-L1 checkpoint inhibition in improving outcomes for LFS-associated GBM patients. https://thejns.org/doi/10.3171/CASE24539.
Authors
- Leonard H. Verhey (ORCID: https://orcid.org/0000-0003-4325-3131)
- Todd W. Vitaz (ORCID: https://orcid.org/0000-0002-8711-3133)
- Andres Restrepo-Orozco
- Melissa P. Mitchell (ORCID: https://orcid.org/0000-0003-4390-9372)
Institutions
- Grand Rapids Community College (US)
- Neurological Surgery (US)
- Corewell Health
- Michigan State University (US)
Publication Details
- Journal
- Journal of Neurosurgery Case Lessons
- Published
- 2024-11-25
- DOI
- https://doi.org/10.3171/case24539
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00